Recursion Pharmaceuticals Prices $200 Million Stock Offering
The biotech firm eyes $200 million in gross proceeds following the pricing of over 61 million shares.
Updated on Oct. 15, 2026 in Biotech
Live Poll
Is now a good time for individual investors to buy shares in clinical-stage biotech companies?
Recursion Pharmaceuticals has priced an underwritten public offering of 61,540,000 shares of its Class A common stock at $3.25 per share. The Salt Lake City-based biotech firm expects to generate approximately $200 million in gross proceeds from the transaction.
Why it matters
The capital raise provides the company with additional liquidity to support its ongoing research and operational activities. This offering follows the initial effectiveness of the registration statement in February 2025.
The public offering includes 61,540,000 shares of Class A common stock priced at $3.25 per share. This financial structure follows the company's registration statement filed on Form S-3, which first became effective in February 2025.
The players
Recursion Pharmaceuticals
A Salt Lake City-based biotechnology firm that integrates machine learning and automated wet-lab experimentation into drug discovery workflows.
The details
The offering is being managed by four joint bookrunning managers and one lead manager. These shares are being issued pursuant to a registration statement on Form S-3, a streamlined filing used by companies that have already met certain SEC reporting requirements. Recursion operates with a focus on using digital tools to map biology and chemistry, maintaining infrastructure across Salt Lake City, London, Montréal, and New York.
Timeline
February 12, 2025: The registration statement for the offering became effective.
October 15, 2026: The company announced the pricing of its stock offering.
October 16, 2026: The offering is expected to close.
The Tech Race
Recursion utilizes the Form S-3 registration process to expedite its capital access, a common mechanism for biotech firms scaling their digital drug-discovery platforms. This funding round supports the ongoing competition to integrate high-throughput laboratory automation with proprietary AI models.
The capital influx is intended to bolster the company's operational capacity as it continues its drug discovery research. For industry observers, this infusion of $200 million signals continued investor backing for AI-driven pharmaceutical development.
The takeaway
This $200 million raise provides the runway needed to continue scaling the company's automated laboratory infrastructure. Watch for upcoming quarterly updates or official 8-K filings for details on how these funds are allocated toward specific research milestones.
What happens next
The offering is scheduled to close on or about October 16, 2026.
Further reading
For broader trends in the industry, visit the Biotech section.
More information
Access the latest company disclosures on the SEC website for filing access.
Live Poll
Is now a good time for individual investors to buy shares in clinical-stage biotech companies?
